| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/10/2004 | US6689355 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| 02/10/2004 | US6689353 Stabilized with histidine, glycine and sucrose |
| 02/10/2004 | US6689350 Therapeutic polyesters and polyamides |
| 02/10/2004 | US6689338 Bioconjugates of nanoparticles as radiopharmaceuticals |
| 02/10/2004 | US6689337 Vitronectin receptor antagonist pharmaceuticals |
| 02/10/2004 | CA2223551C Benzimidazole compounds |
| 02/10/2004 | CA2114936C Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones |
| 02/10/2004 | CA2109053C Stabilised hexadecylphosphocholine solutions in glycerol alkyl ethers |
| 02/09/2004 | CA2398828A1 A pharmaceutical composition containing an indolopyrrolocarbazole derivative |
| 02/05/2004 | WO2004011673A1 Auto-stimulating cells and method for making and using the same |
| 02/05/2004 | WO2004011662A1 Persulfated oligosaccharide acting on selectins and chemokine |
| 02/05/2004 | WO2004011661A1 Novel physiologically active substances |
| 02/05/2004 | WO2004011640A1 Three-dimensional structure of dipeptidyl peptidase iv |
| 02/05/2004 | WO2004011625A2 Polymorphisms for predicting disease and treatment outcome |
| 02/05/2004 | WO2004011611A2 Taci antibodies and uses thereof |
| 02/05/2004 | WO2004011486A2 Method for solubilizing hydrophobic peptides and use thereof for inducing an antitumoral and/or anti-infectious ctl response |
| 02/05/2004 | WO2004011481A1 Phosmidosine derivative and process for producing the same |
| 02/05/2004 | WO2004011476A1 Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer |
| 02/05/2004 | WO2004011469A1 Cell differentiation inductor |
| 02/05/2004 | WO2004011465A1 Kinase inhibitors |
| 02/05/2004 | WO2004011464A2 Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same |
| 02/05/2004 | WO2004011461A1 Isothiazole derivatives useful as anticancer agents |
| 02/05/2004 | WO2004011460A2 Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
| 02/05/2004 | WO2004011459A1 Novel physiologically active substance |
| 02/05/2004 | WO2004011458A1 Total synthesis of myriaporones |
| 02/05/2004 | WO2004011456A1 Protein tyrosine kinase inhibitors |
| 02/05/2004 | WO2004011443A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 02/05/2004 | WO2004011423A2 Structural carotenoid analogs for the inhibition and amelioration of disease |
| 02/05/2004 | WO2004011418A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc-chemokine receptor ligands |
| 02/05/2004 | WO2004011402A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | WO2004011004A1 Formulation of liposomal derivatives of phenylalanine |
| 02/05/2004 | WO2004011000A1 Parenteral formulations containing a rapamycin hydroxyester |
| 02/05/2004 | WO2004010995A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |
| 02/05/2004 | WO2004010977A1 Method for decreasing bioavailability variability of an orally administered medicine |
| 02/05/2004 | WO2004010974A2 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | WO2004010973A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | WO2004010972A2 Pellicle-resistant gelatin capsule |
| 02/05/2004 | WO2004010957A2 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 02/05/2004 | WO2004010951A2 Method of treating tumors |
| 02/05/2004 | WO2004010947A2 Humanized antibodies against human 4-1bb |
| 02/05/2004 | WO2004010945A2 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | WO2003097871A3 Marker molecules associated with lung tumors |
| 02/05/2004 | WO2003094829A3 Pathogen vaccines and methods for using the same |
| 02/05/2004 | WO2003094828A3 Cancer vaccines and methods of using the same |
| 02/05/2004 | WO2003093320A3 Antibodies specific for human cd22 and their therapeuatic and digagnostic uses |
| 02/05/2004 | WO2003089624A3 Fc receptor homolog, reagents, and uses thereof |
| 02/05/2004 | WO2003089001A8 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus |
| 02/05/2004 | WO2003087818A3 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
| 02/05/2004 | WO2003086461A3 Use of substances for treating tumors |
| 02/05/2004 | WO2003084996A3 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine |
| 02/05/2004 | WO2003084938A3 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases |
| 02/05/2004 | WO2003083442A3 Life sciences business systems and methods |
| 02/05/2004 | WO2003082919A3 Ox40r binding agents |
| 02/05/2004 | WO2003075857A3 Amino-methyl substituted tetracycline compounds |
| 02/05/2004 | WO2003074654A3 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 02/05/2004 | WO2003074062A3 Isolation, purification and structural identification of a bioactive component of a water soluble extract of a botanical species for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals |
| 02/05/2004 | WO2003070703A3 Hydroxylated indirubin derivatives |
| 02/05/2004 | WO2003055911A8 Cystine-knot fold protein |
| 02/05/2004 | WO2003020947A3 Mid 9002, a human sulfatase family member and uses therefor |
| 02/05/2004 | WO2003016915A8 Tumor specific oligosaccharide sequences and use thereof |
| 02/05/2004 | WO2002087555A3 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer |
| 02/05/2004 | WO2002059373A3 Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
| 02/05/2004 | US20040025199 Comprises g-protein couple receptors for identifying modulators of g-protein activity and diagnosis and treatment of infections, nervous system, tumor, autoimmune and inflammatory disorders |
| 02/05/2004 | US20040024450 Drug-delivery endovascular stent and method for treating restenosis |
| 02/05/2004 | US20040024363 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/05/2004 | US20040024231 Such as 17-beta-hydroxy-17-alpha-trifluoromethyl-7-alpha-methyl-androst-4-en-3-one; for hormone replacement therapy |
| 02/05/2004 | US20040024208 Cyclic protein tyrosine kinase inhibitors |
| 02/05/2004 | US20040024197 Synthetic oligo- and polysaccharides exhibiting at least one covalent bond with biotin or a biotin derivative and having the anticoagulant and antithrombotic pharmacological activities of heparin |
| 02/05/2004 | US20040024179 Comprises peptide with heparin and/or lipopolysaccharide binding activity for use as treatment of endotoxic shock and endometriosis, anticoagulant, angiogenesis inhibitor, antiproliferative agent and contraceptive |
| 02/05/2004 | US20040024063 Fatty acid analogues for the treatment of cancer |
| 02/05/2004 | US20040024062 Inhibiting a condition mediated by the alpha v beta 3 or alpha v beta 5 integrin; antitumor, -metastasis, -arthritic agents; angiogenesis, inhibitors; osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration |
| 02/05/2004 | US20040024060 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/05/2004 | US20040024057 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications |
| 02/05/2004 | US20040024055 Compounds HNP-98701A (epi-manassantin A), HNP-98701B and HNP-98701C (manassantin A) as carcinostatis substances |
| 02/05/2004 | US20040024051 C10 heterosubstituted acetate taxanes |
| 02/05/2004 | US20040024049 Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| 02/05/2004 | US20040024044 In chemoprevention of estrogen dependent cancer in mammals, including humans |
| 02/05/2004 | US20040024040 Inhibitors of GSK-3 and uses thereof |
| 02/05/2004 | US20040024039 Having a steroid C17,20-lyase inhibitory activity; useful as prophylactic or therapeutic agent for prostate and breast cancers |
| 02/05/2004 | US20040024035 Oxazole derivatives useful as growth factor receptor tyrosine kinase (particularly HER2) inhibitors; for preventing or treating cancer |
| 02/05/2004 | US20040024033 Cancer treatment with epothilones |
| 02/05/2004 | US20040024029 Thiazole and oxazole derivatives |
| 02/05/2004 | US20040024025 Compositions and methods for inducing cell death |
| 02/05/2004 | US20040024024 Inhibiting matrix metalloproteinase and aggrecanase activity; for treatment of strokes and neurodegenerative diseases |
| 02/05/2004 | US20040024015 Enhancing chemotherapy/radition therapy; endothelial growth factors; side effects reduction |
| 02/05/2004 | US20040024014 Such as 2-(nitrooxy)ethyl-2-(((3-methyl-4-(2,2,2-trifluoro-ethoxy)-2 -pyridyl)methyl)sulfinyl)benzimidazolecarboxylate; kits; for treating gastrointestinal disorders/ulcers |
| 02/05/2004 | US20040024001 Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases |
| 02/05/2004 | US20040024000 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 02/05/2004 | US20040023999 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 02/05/2004 | US20040023998 2-(5-amino-6-oxo-2-phenyl-1,6-dihydro-1-pyrimidyl)-N-(1-(2-(5-t -butyl-1,3,4-oxadiazolyl)carbonyl)-2-(R,S)-methylpropyl) acetamide; elastase inhibitors |
| 02/05/2004 | US20040023996 Methods and compositions utilizing quinazolinones |
| 02/05/2004 | US20040023992 Antiinflammatory agents |
| 02/05/2004 | US20040023991 Use of pyrazolo[4,3-d]pyrimidines |
| 02/05/2004 | US20040023990 Use of pyrazolo[4,3-d]pyrimidines |
| 02/05/2004 | US20040023976 Treatment of gastrointestinal stromal tumors |
| 02/05/2004 | US20040023974 Pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present |
| 02/05/2004 | US20040023963 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| 02/05/2004 | US20040023961 Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| 02/05/2004 | US20040023950 N-heterocyclic derivatives as NOS inhibitors |
| 02/05/2004 | US20040023945 Cyclic amp-specific phosphodiesterase inhibitors |